Previous close | 1.8050 |
Open | 1.8770 |
Bid | 1.9900 x 0 |
Ask | 2.0980 x 0 |
Day's range | 1.8770 - 2.1000 |
52-week range | 1.1000 - 46.7000 |
Volume | |
Avg. volume | 200,430 |
Market cap | 74.085M |
Beta (5Y monthly) | 1.07 |
PE ratio (TTM) | N/A |
EPS (TTM) | -17.9400 |
Earnings date | 20 Sept 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 108.00 |
KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.
Orphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise.
Orphazyme AS Sponsored ADR (ORPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.